Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2008



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Alzheimer's Disease (C7)


Organizer(s) David M. Holtzman, Dora M. Kovacs and Cynthia A. Lemere
March 24—29, 2008
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Nov 26, 2007
Late Abstract Deadline: Dec 26, 2007
Scholarship Deadline: Nov 26, 2007
Early Registration Deadline: Jan 25, 2008

Supported by the Director's Fund

Summary of Meeting:
Aggregation of the amyloid ß peptide and tau in the brain are key events in Alzheimer’s disease (AD). The understanding of the cell biological processes that lead to Aß formation is advancing rapidly. The cellular release, transport, and clearance of Aß and how Aß influences tau are just beginning to be understood. Studies of pathogenesis and treatment of AD with cellular and animal models are promising. Recent data in humans indicates that fluid and imaging biomarkers for both clinical and pre-clinical AD may be possible. Several pivotal issues that remain are: (1) to develop a full understanding of APP, A beta, and tau biology; (2) to be able to predict AD prior to cognitive decline; and (3) to develop effective methods to prevent and treat AD. The goal of this meeting will be to provide a state of the art update of the genetic, molecular, cell biological, and translational aspects of AD. Integration of current and novel bench and translational science in this area should lead to new ideas and collaborations.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


MONDAY, MARCH 24

15:00—19:30
Registration

Shavano Peak Foyer
18:30—19:30
Refreshments

Shavano Peak Foyer
19:30—21:15
Keynote Session
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
Christian Haass, Ludwig-Maximilians University Munich, Germany
The Process of Amyloid ß-Peptide generation: Normal and Disease Biology

Dennis J. Selkoe, Harvard Medical School, USA
The End Game in Alzheimer’s Disease: Translating Molecular Mechanisms into Therapeutics


TUESDAY, MARCH 25

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:00
Clinical, Epidemiological, and Genetic Factors Relevant to AD and Related Disorders
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* David M. Holtzman, Washington University, USA

John Morris, Alzheimer Disease & Associated Disorders, USA
Preclinical AD and PreMCI: The Future of Alzheimer Research

Rudolph E. Tanzi, Massachusetts General Hospital, USA
The Continuing Search for Novel Alzheimer's Disease Genes

Lenore J. Launer, National Institute on Aging, USA
Cardiovascular and Non-Genetic Risk Factors for AD

Elizabeth H. Corder, Duke University, USA
Short Talk: Genetic Risk Profiles for Alzheimer’s Disease: Integration of APOE Genotype and Variants that Up-Regulate Inflammation

Peter J. Hudson, Aviper, Pty., Ltd., Australia
Short Talk: Early Stage Alzheimer’s Disease Diagnosis in a Unique Progressing Cohort by Correlation of Cognition, Neuroimaging and Blood Biomarkers (the AIBL Cluster Study).

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Shavano/Torreys
13:00—22:00
Poster Viewing

Shavano/Torreys
16:30—17:00
Coffee Available

Shavano Peak Foyer
17:00—19:00
APP Processing, Function, and Cell Biology of Neurodegeneration
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA

Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA
Pathophysiological Functions of APP: A Potential Function of APP Metabolite AICD in EGFR Signaling and Apoptotic Neuronal Cell Death

Gopal Thinakaran, University of Chicago, USA
APP Processing in Lipid Rafts

Hui Zheng, Baylor College of Medicine, USA
Role of APP in Synaptic Structure and Function

Patricia V. Burgos, NICHD, National Institutes of Health, USA
Short Talk: The AP4 Complex Mediates Sorting of the Amyloid Precursor Protein at the trans-Golgi Network

19:00—20:00
Social Hour with Lite Bites

Shavano/Torreys
19:30—22:00
Poster Session 1

Shavano/Torreys

WEDNESDAY, MARCH 26

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:15
Abeta Metabolism, CAA, and Blood-Brain-Barrier
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA

Randall Bateman, Washington University School of Medicine, USA
APP/Abeta Synthesis and Clearance in Humans

Mathias Jucker, Hertie-Institute for Clinical Brain Research and DZNE, Germany
Mouse Models of Cerebral Abeta and Non-Abeta Amyloid Angiopathies

William E. Van Nostrand, Stony Brook University, USA
Tg-SwDI: A Mouse Model to Investigate Cerebral Microvascular Amyloid, Neuroinflammation, and Behavioral Deficits

Donna M. Wilcock, Duke University, USA
Short Talk: Neurovascular Unit Changes are Observed in Association with Cerebral Amyloid Angiopathy in Several Mouse Models of Alzheimer’s Disease

Bruce T. Lamb, Indiana University School of Medicine, USA
Short Talk: The Role of Inflammation and Beta-Amyloid Oligomers in Triggering Aberrant Neuronal Cell Cycle Events

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:15—13:00
Poster Setup

Shavano/Torreys
13:00—22:00
Poster Viewing

Shavano/Torreys
16:30—17:00
Coffee Available

Shavano Peak Foyer
17:00—19:00
BACE and Gamma-Secretase
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* David M. Holtzman, Washington University, USA

Michael S. Wolfe, Brigham and Women's Hospital, Harvard Medical School, USA
Biochemistry and Inhibition of Gamma-Secretase and Presenilin-like Proteases

Takeshi Iwatsubo, University of Tokyo, Japan
Structure and Function of the gamma-Secretase Complex

Robert J. Vassar, Northwestern University Medical School, USA
The Role of BACE1 in Alzheimer's Disease

Doo Yeon Kim, Harvard Medical School, Massachusetts General Hospital, USA
Short Talk: BACE1 and gamma-Secretase Regulate Voltage-Gated Sodium Channel Metabolism

19:00—20:00
Social Hour with Lite Bites

Shavano/Torreys
19:30—22:00
Poster Session 2

Shavano/Torreys

THURSDAY, MARCH 27

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:15
Tau Function and Dysfunction in AD and Related Disorders
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* David M. Holtzman, Washington University, USA

Kurt R. Brunden, University of Pennsylvania, USA
Tau Focused Drug Discovery for Alzheimer’s Disease and Related Tauopathies

Fred Van Leuven, Experimental Genetics Group - KU Leuven, Belgium
Tau Phosphorylation and Tauopathy in Mouse Models: Amyloid Activates GSK3

Karen Hsiao Ashe, University of Minnesota, USA
Toward Understanding the Molecular Basis of Tau-induced Memory Loss

Erik D. Roberson, University of Alabama at Birmingham, USA
Tau and Neuronal Dysfunction

Tudor A. Fulga, University of Oxford, UK
Short Talk: Actin Cytoskeleton – A Critical Mediator of Neuronal Degeneration in Alzheimer Disease

George S. Bloom, University of Virginia, USA
Short Talk: Tau-Dependent Microtubule Loss Induced by Pre-Fibrillar Beta-amyloid

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:15—13:00
Poster Setup

Shavano/Torreys
13:00—22:00
Poster Viewing

Shavano/Torreys
16:30—17:00
Coffee Available

Shavano Peak Foyer
17:00—19:00
Biomarkers and Imaging
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* David M. Holtzman, Washington University, USA

* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA

Anne M. Fagan, Washington University School of Medicine, USA
CSF and Amyloid Imaging Biomarkers in AD

Tony Wyss-Coray, Stanford University School of Medicine, USA
Plasma protein biomarkers for aging and Alzheimer's disease

Reisa A. Sperling, Brigham and Women's Hospital, Harvard Medical School, USA
Functional and Molecular Imaging in Early AD

Jessica Koenigsknecht-Talboo, Washington University, USA
Short Talk: Dynamic Imaging of Microglia and Abeta Deposition: Evidence of Rapid Responses Following Systemic Anti-Abeta Antibody Administration

19:00—20:00
Social Hour with Lite Bites

Shavano/Torreys
19:30—22:00
Poster Session 3

Shavano/Torreys

FRIDAY, MARCH 28

07:00—08:00
Breakfast

Shavano/Torreys
08:00—11:15
Therapeutics
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA

Ronald B. DeMattos, Lilly Research Laboratories, USA
Update on Active and Passive Immunotherapy

Gerald Koelsch, Astellas Pharma, USA
Beta-Secretase Inhibitor CTS-21166 Reduces Plasma Abeta40 in Human Subjects

JoAnne McLaurin, University of Toronto, Canada
Novel Small Molecule Therapies for AD

Takaomi C. Saido, RIKEN Brain Science Institute, Japan
N-Terminal Modification of Amyloid-beta Peptide, AbetaX-42, in Alzheimer's Disease and Mouse Models

Hans-Ulrich Demuth, Probiodrug AG, Germany
Short Talk: Prevention of Abeta3(pE)-42 Formation: A New Causative Treatment Paradigm in AD

Jonathan Thomas Megerian, Epix Pharmaceuticals, USA
Short Talk: Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer’s Disease

09:20—09:40
Coffee Break

Shavano Peak Foyer
16:30—17:00
Coffee Available

Shavano Peak Foyer
17:00—19:00
Therapeutics II
Meeting has ended...abstracts no longer viewable online.

Red Cloud Peak
* David M. Holtzman, Washington University, USA

Steven L. Wagner, TorreyPines Therapeutics, USA
Modulation of the Gamma Secretase Enzyme Complex with Orally Bioavailable Small Molecules

Frank M. La Ferla, University of California, Irvine, USA
Reversing age-dependent memory impairments in a transgenic model of Alzheimer disease

William James Ray, Merck & Co. Inc., USA
Targeting Pathways that Lead to the Accumulation of Amyloid

Michael Bacher, Philipp-University Marburg, Germany
Short Talk: Administration of CNI-1493 inhibits Aß accumulation, amyloid plaque formation, and cognitive deterioration in an animal model of Alzheimer’s disease

19:00—20:00
Social Hour with Lite Bites

Shavano/Torreys
20:00—23:00
Entertainment

Shavano/Torreys

SATURDAY, MARCH 29

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:


Alzheimer's Association

Alzheimer's Drug Discovery Foundation
Merck & Co., Inc.
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Merck & Co., Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676